|
|
Article: GENOSPECTRA SERIES C RAISES $16.4M FOR NEXT PQB STEPS.
- Article from:
- BIOWORLD Today
- Article date:
- September 15, 2004
- Author:
CopyrightCOPYRIGHT 2004 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Randall Osborne, West Coast Editor
Privately held genomics tools company Genospectra Inc. gained $16.4 million in a Series C financing to advance its Parallel Quantitative Biology initiative.
"The cash [on hand] will certainly suffice for well over two years," said Frank Witney, president and CEO of Fremont, Calif.-based Genospectra, adding that the company is targeting profitability in 2006.
Genospectra's technology - designed to be of particular benefit with RNA interference, predictive toxicology and secondary screening - includes cell-based assays for gene-expression profiling and live-cell biosensors for analysis of protein or nucleic acid ...